Clovis Oncology
Edit

Clovis Oncology

https://clovisoncology.com/
Last activity: 04.10.2022
Tags:BioTechDevelopmentDiagnosticsDrugHealthTechLivingManagementMedtechMovingPublic
Clovis Oncology is advancing the fight against cancer. Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy. Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer. Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado. Please visit our website for more information, including additional office locations in the U.S. and Europe.
Mentions
14
Location: United States, Colorado, Boulder
Employees: 201-500
Total raised: $275M
Founded date: 2009

Investors 7

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
18.06.2013-$275M-xconomy.co...

Mentions in press and media 14

DateTitleDescriptionSource
04.10.2022Pfiz­er’s PARP in­hibitor com­bo treat­ment pass­es pri­ma­r...Pfiz­er ac­quired both Xtan­di and Talzen­na, a PARP in­hibitor, in its $14 bil­lion buy­out of Medi...endpts.com...
31.03.2022Clovis Stock Is Soaring. The Biotech’s Ovarian Cancer Drug L...Shares of the small biotech firm Clovis Oncology jumped more than 40% on Thursday, after the company...barrons.co...
24.08.2021Clovis Oncology : Announces Availability of and Reimbursemen...Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and r...marketscre...
19.03.2021Clovis Oncology’s Rubraca® (rucaparib) Significantly Improve...BOULDER, Colo.--(BUSINESS WIRE)--Mar 19, 2021-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced that...oaoa.com/n...
18.05.2020Clo­vis' Rubra­ca wins prostate can­cer ap­proval, but da­ta...While As­traZeneca and Mer­ck’s mar­ket-lead­ing Lyn­parza seem­ing­ly pipped Clo­vis On­col­o­gy’s ...endpts.com...
03.12.2018GlaxoSmithKline to buy cancer-focused Tesaro for $5.1 billio...Tesaro’s only marketed product is Zejula (niraparib), a PARP inhibitor approved for the maintenance ...medcitynew...
25.03.2015This entrepreneur nearly lost his company. Here’s how litiga...In 2009, Chant, who had previously founded G-Zero Therapeutics (now G-One Therapeutics), heard about...medcitynew...
20.11.2013Clovis Oncology Acquires Ethical Oncology Science for up to ...Clovis Oncology (NASDAQ:CLVS), a Boulder, Colorado-based biopharmaceutical company focused on acquir...finsmes.co...
17.10.2013Clovis Oncology CEO Mahaffy Opens Up About Company’s Turbule...Share Share on Facebook Share on Twitter LinkedIn Email Reprints Seeing your cornerstone product “f...xconomy.co...
18.06.2013Clovis Oncology Closes $275M Offering Following Two Pivotal ...Share Share on Facebook Share on Twitter LinkedIn Email Reprints Clovis Oncology’s big two weeks ca...xconomy.co...
Show more